HMGB1, IL-1α, IL-33 and S100 proteins: Dual-function alarmins

Cellular and Molecular Immunology

Volumn 14, Issue 1, 2017, Pages 43-64

  Bertheloot, Damien ^a   Latz, Eicke ^a,b,c  

^a UNIVERSITY OF BONN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

alarmin; HMGB1; IL 1 ; IL 33; inflammation; S100 proteins

Indexed keywords

ALARMIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 33; PROTEIN S 100;

ACUTE DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELLULAR DISTRIBUTION; CHRONIC INFLAMMATION; HUMAN; HYPOXIA; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFECTION; INFLAMMATORY DISEASE; MALIGNANT NEOPLASM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; TISSUE INJURY; ANIMAL; BIOLOGICAL MODEL; METABOLISM;

ALARMINS; ANIMALS; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-1ALPHA; INTERLEUKIN-33; MODELS, BIOLOGICAL; S100 PROTEINS;

EID: 85007557081     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2016.34     Document Type: Review

References (310)

1. Janeway CA. Pillars article: approaching the asymptote? Evolution and revolution in immunology. Cold spring harb symp quant boil. 1989. 54: 1-13.
2. J Immunol 2013; 191: 4475-4487.
3. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
4. Seong S-Y, Matzinger P. Hydrophobicity: an ancient damageassociated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004; 4: 469-478.
5. Bessa J, Meyer CA, de Vera Mudry MC, Schlicht S, Smith SH, Iglesias A et al. Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation. J Autoimmun 2014; 55: 33-41.
6. Agresti A, Bianchi ME. HMGB proteins and gene expression. Curr Opin Genet Dev 2003; 13: 170-178.
7. Stros M. HMGB proteins: interactions with DNA and chromatin. Biochim Biophys Acta 2010; 1799: 101-113.
8. Stott K, Watson M, Howe FS, Grossmann JG, Thomas JO. Tail-mediated collapse of HMGB1 is dynamic and occurs via differential binding of the acidic tail to the A and B domains. J Mol Biol 2010; 403: 706-722.
9. Ito I, Fukazawa J, Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 2007; 282: 16336-16344.
10. Oh YJ, Youn JH, Ji Y, Lee SE, Lim KJ, Choi JE et al. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J Immunol 2009; 182: 5800-5809.
11. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-5560.
12. Youn JH, Shin J-S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol 2006; 177: 7889-7897.
13. Lu B, Antoine DJ, Kwan K, Lundbäck P, Wähämaa H, Schierbeck H et al. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci USA 2014; 111: 3068-3073.
14. Tang D, Kang R, Zeh HJ, Lotze MT. High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011; 14: 1315-1335.
15. Yang H, Lundbäck P, Ottosson L, Erlandsson-Harris H, Vénéreau E, Bianchi ME et al. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 2012; 18: 250-259.
16. Vénéreau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-1528.
17. Kazama H, Ricci J-E, Herndon JM, Hoppe G, Green DR, Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008; 29: 21-32.
18. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
19. Andersson U, Tracey KJ. 2011HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29: 139-162.
20. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-484.
21. Abraham E, Arcaroli J, Carmody A, Wang H, Tracey KJ. HMG-1 as a mediator of acute lung inflammation. J Immunol 2000; 165: 2950-2954.
22. Degryse B, Bonaldi T, Scaffidi P, Muller S, Resnati M, Sanvito F et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol 2001; 152: 1197-1206.
23. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441-449.
24. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-195.
25. Bell CW, Jiang W, Reich CF, Pisetsky DS. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: C1318-C1325.
26. Jiang W, Bell CW, Pisetsky DS. The relationship between apoptosis and high-mobility group protein 1 release from murine macrophages stimulated with lipopolysaccharide or polyinosinic-polycytidylic acid. J Immunol 2007; 178: 6495-6503.
27. Qin S, Wang H, Yuan R, Li H, Ochani M, Ochani K et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203: 1637-1642.
28. Willingham SB, Allen IC, Bergstralh DT, Brickey WJ, Huang MT-H, Taxman DJ et al. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol 2009; 183: 2008-2015.
29. Lu B, Wang H, Andersson U, Tracey KJ. Regulation of HMGB1 release by inflammasomes. Protein Cell 2013; 4: 163-167.
30. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
31. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H et al. IFN-gamma induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003; 170: 3890-3897.
32. Lamkanfi M, Sarkar A, Vande Walle L, Vitari AC, Amer AO, Wewers MD et al. 2010Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 185: 4385-4392.
33. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME et al. The nuclear protein HMGB1 is secreted by monocytes via a nonclassical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995-1001.
34. Ponpuak M, Mandell MA, Kimura T, Chauhan S, Cleyrat C, Deretic V. Secretory autophagy. Curr Opin Cell Biol 2015; 35: 106-116.
35. Deretic V, Saitoh T, Akira S. Autophagy in infection, inflammation and immunity. Nat Rev Immunol 2013; 13: 722-737.
36. Tang D, Kang R, Livesey KM, Cheh C-W, Farkas A, Loughran P et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010; 190: 881-892.
37. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-11947.
38. Yang H, Wang H, Ju Z, Ragab AA, Lundbäck P, Long W et al. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 2015; 212: 5-14.
39. Youn JH, Oh YJ, Kim ES, Choi JE, Shin J-S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes. J Immunol 2008; 180: 5067-5074.
40. Chen G-Y, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009; 323: 1722-1725.
41. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 1995; 270: 25752-25761.
42. Rauvala H, Merenmies J, Pihlaskari R, Korkolainen M, Huhtala ML, Panula P. The adhesive and neurite-promoting molecule p30: analysis of the amino-terminal sequence and production of antipeptide antibodies that detect p30 at the surface of neuroblastoma cells and of brain neurons. J Cell Biol 1988; 107: 2293-2305.
43. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84-91.
44. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506-7515.
45. Manfredi AA, Capobianco A, Esposito A, De Cobelli F, Canu T, Monno A et al. Maturing dendritic cells depend on RAGE for in vivo homing to lymph nodes. J Immunol 2008; 180: 2270-2275.
46. Abeyama K, Stern DM, Ito Y, Kawahara K-I, Yoshimoto Y, Tanaka M et al. The N-terminal domain of thrombomodulin sequesters highmobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115: 1267-1274.
47. Treutiger CJ, Mullins GE, Johansson A-SM, Rouhiainen A, Rauvala HME, Erlandsson-Harris H et al. High mobility group 1 B-box mediates activation of human endothelium. J Intern Med 2003; 254: 375-385.
48. Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-2660.
49. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008; 180: 2531-2537.
50. Schiraldi M, Raucci A, Muñoz LM, Livoti E, Celona B, Vénéreau E et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 2012; 209: 551-563.
51. Urbonaviciute V, Fürnrohr BG, Meister S, Munoz L, Heyder P, De Marchis F et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J Exp Med 2008; 205: 3007-3018.
52. Ivanov S, Dragoi A-M, Wang X, Dallacosta C, Louten J, Musco G et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 2007; 110: 1970-1981.
53. Yanai H, Ban T, Wang Z, Choi MK, Kawamura T, Negishi H et al. HMGB proteins function as universal sentinels for nucleic-acidmediated innate immune responses. Nature 2009; 462: 99-103.
54. Tian J, Avalos AM, Mao S-Y, Chen B, Senthil K, Wu H et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol 2007; 8: 487-496.
55. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H et al. Tumor-infiltrating DCs suppress nucleic acidmediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-842.
56. Rouhiainen A, Tumova S, Valmu L, Kalkkinen N, Rauvala H. Pivotal advance: analysis of proinflammatory activity of highly purified eukaryotic recombinant HMGB1 (amphoterin). J Leukoc Biol 2007; 81: 49-58.
57. Andersson U, Tracey KJ. HMGB1 in sepsis. Scand J Infect Dis 2003; 35: 577-584.
58. Nagato M, Okamoto K, Abe Y, Higure A, Yamaguchi K. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37: 2181-2186.
59. Yanai H, Matsuda A, An J, Koshiba R, Nishio J, Negishi H et al. Conditional ablation of HMGB1 in mice reveals its protective function against endotoxemia and bacterial infection. Proc Natl Acad Sci USA 2013; 110: 20699-20704.
60. Yamato M, Minematsu Y, Fujii J, Mori K, Minato T, Miyagawa S et al. Effective combination therapy of polymyxin-B direct hemoperfusion and recombinant thrombomodulin for septic shock accompanied by disseminated intravascular coagulation: a historical controlled trial. Ther Apher Dial 2013; 17: 472-476.
61. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE et al. Reversing established sepsis with antagonists of endogenous highmobility group box 1. Proc Natl Acad Sci USA 2004; 101: 296-301.
62. Lutterloh EC, Opal SM, Pittman DD, Keith JC, Tan X-Y, Clancy BM et al. Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care 2007; 11: R122.
63. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-1650.
64. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201: 1135-1143.
65. Tsung A, Zheng N, Jeyabalan G, Izuishi K, Klune JR, Geller DA et al. Increasing numbers of hepatic dendritic cells promote HMGB1- mediated ischemia-reperfusion injury. J Leukoc Biol 2007; 81: 119-128.
66. Krüger B, Krick S, Dhillon N, Lerner SM, Ames S, Bromberg JS et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc Natl Acad Sci USA 2009; 106: 3390-3395.
67. Andrassy M, Volz HC, Igwe JC, Funke B, Eichberger SN, Kaya Z et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008; 117: 3216-3226.
68. Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 2006; 25: 571-574.
69. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ et al. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci 2008; 28: 12023-12031.
70. Weber DJ, Gracon ASA, Ripsch MS, Fisher AJ, Cheon BM, Pandya PH et al. The HMGB1-RAGE axis mediates traumatic brain injury- induced pulmonary dysfunction in lung transplantation. Sci Transl Med 2014; 6: 252ra124.
71. Nicolls MR, Laubach VE. Traumatic brain injury: lungs in a RAGE. Sci Transl Med 2014; 6: 252fs34.
72. Sodhi CP, Jia H, Yamaguchi Y, Lu P, Good M, Egan C et al. Intestinal epithelial TLR-4 activation is required for the development of acute lung injury after trauma/hemorrhagic shock via the release of HMGB1 from the gut. J Immunol 2015; 194: 4931-4939.
73. Liu K, Mori S, Takahashi HK, Tomono Y, Wake H, Kanke T et al. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007; 21: 3904-3916.
74. Yang R, Harada T, Mollen KP, Prince JM, Levy RM, Englert JA et al. Anti-HMGB1 neutralizing antibody ameliorates gut barrier dysfunction and improves survival after hemorrhagic shock. Mol Med 2006; 12: 105-114.
75. Kang R, Zhang Q, Zeh HJ, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013; 19: 4046-4057.
76. Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007; 13: 2836-2848.
77. Chung HW, Lee S-G, Kim H, Hong DJ, Chung JB, Stroncek D et al. Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38.
78. Poser I, Golob M, Buettner R, Bosserhoff AK. Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol 2003; 23: 2991-2998.
79. Yan W, Chang Y, Liang X, Cardinal JS, Huang H, Thorne SH et al. High mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 2012; 55: 1863-1875.
80. Kang R, Tang D, Schapiro NE, Loux T, Livesey KM, Billiar TR et al. The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics. Oncogene 2014; 33: 567-577.
81. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290-3301.
82. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene 2013; 32: 363-374.
83. Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014; 507: 109-113.
84. van Beijnum JR, Dings RP, van der Linden E, Zwaans BMM, Ramaekers FCS, Mayo KH et al. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 2006; 108: 2339-2348.
85. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
86. Tang D, Loze MT, Zeh HJ, Kang R. The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 2010; 6: 1181-1183.
87. Tang D, Kang R, Cheh C-W, Livesey KM, Liang X, Schapiro NE et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310.
88. Liu L, Yang M, Kang R, Wang Z, Zhao Y, Yu Y et al. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia 2011; 25: 23-31.
89. Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 2012; 72: 1996-2005.
90. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17: 666-676.
91. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
92. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.
93. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 2002; 46: 2598-2603.
94. Taniguchi N, Kawahara K-I, Yone K, Hashiguchi T, Yamakuchi M, Goto M et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003; 48: 971-981.
95. Pullerits R, Jonsson I-M, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H et al. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum 2003; 48: 1693-1700.
96. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T et al. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 2008; 58: 2675-2685.
97. Liu-Bryan R, Terkeltaub R. Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum 2010; 62: 2004-2012.
98. Kokkola R, Li J, Sundberg E, Aveberger A-C, Palmblad K, Yang H et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003; 48: 2052-2058.
99. van de Wouwer M, Plaisance S, De Vriese A, Waelkens E, Collen D, Persson J et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4: 1813-1824.
100. Ostberg T, Wähämaa H, Palmblad K, Ito N, Stridh P, Shoshan M et al. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther 2008; 10: R1.
101. Zetterström CK, Jiang W, Wähämaa H, Ostberg T, Aveberger A-C, Schierbeck H et al. Pivotal advance: inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. J Leukoc Biol 2008; 83: 31-38.
102. Popovic K, Ek M, Espinosa A, Padyukov L, Harris HE, Wahren-Herlenius M et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum 2005; 52: 3639-3645.
103. Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus 2007; 16: 794-802.
104. Li J, Xie H, Wen T, Liu H, Zhu W, Chen X. Expression of high mobility group box chromosomal protein 1 and its modulating effects on downstream cytokines in systemic lupus erythematosus. J Rheumatol 2010; 37: 766-775.
105. Ma C-Y, Jiao Y-L, Zhang J, Yang Q-R, Zhang Z-F, Shen Y-J et al. Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumat Int 2010; 32: 395-402.
106. Abdulahad DA, Westra J, Bijzet J, Limburg PC, Kallenberg CGM, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther 2011; 13: R71.
107. Urbonaviciute V, Voll RE. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus. J Intern Med 2011; 270: 309-318.
108. Porto A, Palumbo R, Pieroni M, Aprigliano G, Chiesa R, Sanvito F et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 2006; 20: 2565-2566.
109. Inoue K, Kawahara K-I, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007; 16: 136-143.
110. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004; 24: 2320-2325.
111. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
112. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403.
113. Harja E, Bu D-X, Hudson BI, Chang JS, Shen X, Hallam K et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest 2008; 118: 183-194.
114. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031.
115. Luo Y, Li S-J, Yang J, Qiu Y-Z, Chen F-P. HMGB1 induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathway. Biochem Biophys Res Commun 2013; 438: 732-738.
116. Deegan S, Saveljeva S, Gorman AM, Samali A. Stress-induced selfcannibalism: on the regulation of autophagy by endoplasmic reticulum stress. Cell Mol Life Sci 2013; 70: 2425-2441.
117. Ahrens I, Chen Y-C, Topcic D, Bode M, Haenel D, Hagemeyer CE et al. HMGB1 binds to activated platelets via the receptor for advanced glycation end products and is present in platelet rich human coronary artery thrombi. Thromb Haemost 2015; 114: 994-1003.
118. Rider P, Carmi Y, Voronov E, Apte RN. Interleukin-1α. Semin Immunol 2013; 25: 430-438.
119. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
120. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 3720-3732.
121. Aden N, Nuttall A, Shiwen X, de Winter P, Leask A, Black CM et al. Epithelial cells promote fibroblast activation via IL-1alpha in systemic sclerosis. J Invest Dermatol 2010; 130: 2191-2200.
122. Bersudsky M, Luski L, Fishman D, White RM, Ziv-Sokolovskaya N, Dotan S et al. Non-redundant properties of IL-1α and IL-1β during acute colon inflammation in mice. Gut 2014; 63: 598-609.
123. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103: 1253-1260.
124. Buryskova M, Pospisek M, Grothey A, Simmet T, Burysek L. Intracellular interleukin-1alpha functionally interacts with histone acetyltransferase complexes. J Biol Chem 2004; 279: 4017-4026.
125. Maier JA, Statuto M, Ragnotti G. Endogenous interleukin 1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol 1994; 14: 1845-1851.
126. Werman A, Werman-Venkert R, White R, Lee J-K, Werman B, Krelin Y et al. The precursor form of IL-1alpha is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 2004; 101: 2434-2439.
127. Pollock AS, Turck J, Lovett DH. The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J 2003; 17: 203-213.
128. Zamostna B, Novak J, Vopalensky V, Masek T, Burysek L, Pospisek M. N-terminal domain of nuclear IL-1α shows structural similarity to the C-terminal domain of Snf1 and binds to the HAT/core module of the SAGA complex. PLoS One 2012; 7: e41801.
129. Lonnemann G, Shapiro L, Engler-Blum G, Müller GA, Koch KM, Dinarello CA. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosisderived kidney fibroblasts. Kidney Int 1995; 47: 837-844.
130. Kawaguchi Y, Nishimagi E, Tochimoto A, Kawamoto M, Katsumata Y, Soejima M et al. Intracellular IL-1alpha-binding proteins contribute to biological functions of endogenous IL-1alpha in systemic sclerosis fibroblasts. Proc Natl Acad Sci USA 2006; 103: 14501-14506.
131. Yin H, Morioka H, Towle CA, Vidal M, Watanabe T, Weissbach L. Evidence that HAX-1 is an interleukin-1 alpha N-terminal binding protein. Cytokine 2001; 15: 122-137.
132. Kobayashi Y, Yamamoto K, Saido T, Kawasaki H, Oppenheim JJ, Matsushima K. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1 alpha. Proc Natl Acad Sci USA 1990; 87: 5548-5552.
133. Kavita U, Mizel SB. Differential sensitivity of interleukin-1 alpha and -beta precursor proteins to cleavage by calpain, a calcium-dependent protease. J Biol Chem 1995; 270: 27758-27765.
134. Carruth LM, Demczuk S, Mizel SB. Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor. J Biol Chem 1991; 266: 12162-12167.
135. Zheng Y, Humphry M, Maguire JJ, Bennett, MR, Clarke MCH. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity 2013; 38: 285-295.
136. Kuida K, Lippke JA, Ku G, Harding MW, Livingston DJ, Su MS et al. Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science 1995; 267: 2000-2003.
137. Keller M, Rüegg A, Werner S, Beer H-D. Active caspase-1 is a regulator of unconventional protein secretion. Cell 2008; 132: 818-831.
138. Gross O, Yazdi AS, Thomas CJ, Masin M, Heinz LX, Guarda G et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012; 36: 388-400.
139. Brough D, Le Feuvre RA, Wheeler RD, Solovyova N, Hilfiker S, Rothwell NJ et al. Ca2+ Stores and Ca2+ entry differentially contribute to the release of IL-1 and IL-1 from murine macrophages. J Immunol 2003; 170: 3029-3036.
140. Mohan SK, Yu C. The IL1alpha-S100A13 heterotetrameric complex structure: a component in the non-classical pathway for interleukin 1alpha secretion. J Biol Chem 2011; 286: 14608-14617.
141. Mandinova A, Soldi R, Graziani I, Bagala C, Bellum S, Landriscina M et al. S100A13 mediates the copper-dependent stress-induced release of IL-1alpha from both human U937 and murine NIH 3T3 cells. J Cell Sci 2003; 116: 2687-2696.
142. Castillo EF, Dekonenko A, Arko-Mensah J, Mandell MA, Dupont N, Jiang S et al. Autophagy protects against active tuberculosis by suppressing bacterial burden and inflammation. Proc Natl Acad Sci USA 2012; 109: E3168-E3176.
143. Cohen I, Rider P, Carmi Y, Braiman A, Dotan S, White MR et al. Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation. Proc Natl Acad Sci USA 2010; 107: 2574-2579.
144. Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, Dinarello CA et al. Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α. Proc Natl Acad Sci USA 2011; 108: 20684-20689.
145. Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, Lüthi AU et al. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol Cell 2011; 44: 265-278.
146. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. Identification of a membrane-associated interleukin 1 in macrophages. Proc Natl Acad Sci USA 1985; 82: 1204-1208.
147. Conlon PJ, Grabstein KH, Alpert A, Prickett KS, Hopp TP, Gillis S. Localization of human mononuclear cell interleukin 1. J Immunol 1987; 139: 98-102.
148. Brody DT, Durum SK. Membrane IL-1: IL-1 alpha precursor binds to the plasma membrane via a lectin-like interaction. J Immunol 1989; 143: 1183-1187.
149. Kaplanski G, Farnarier C, Kaplanski S, Porat R, Shapiro L, Bongrand P et al. Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. Blood 1994; 84: 4242-4248.
150. Dower SK, Kronheim SR, Hopp TP, Cantrell M, Deeley M, Gillis S et al. The cell surface receptors for interleukin-1 alpha and interleukin-1 beta are identical. Nature 1986; 324: 266-268.
151. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010; 3: cm1.
152. Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E et al. IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol 2011; 187: 4835-4843.
153. Eigenbrod T, Park J-H, Harder J, Iwakura Y, Nuñez G. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. J Immunol 2008; 181: 8194-8198.
154. Chen C-J, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13: 851-856.
155. Rider P, Kaplanov I, Romzova M, Bernardis L, Braiman A, Voronov E et al. The transcription of the alarmin cytokine interleukin-1 alpha is controlled by hypoxia inducible factors 1 and 2 alpha in hypoxic cells. Front Immunol 2012; 3: 290.
156. Dinarello CA, Ikejima T, Warner SJ, Orencole SF, Lonnemann G, Cannon JG et al. Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol 1987; 139: 1902-1910.
157. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-652.
158. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115: 3632-3639.
159. Marquardt L, Ruf A, Mansmann U, Winter R, Schuler M, Buggle F et al. Course of platelet activation markers after ischemic stroke. Stroke 2002; 33: 2570-2574.
160. Sheremata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A. Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 2008; 5: 27.
161. Karakantza M, Maniatis A, Metallinos CI, Papapetropoulos T, Paschalis C. In vivo platelet activation in ischemic stroke patients. Stroke 2003; 34: e174-e175.
162. Turner NA, Das A, Warburton P, O'Regan DJ, Ball SG, Porter KE. Interleukin-1alpha stimulates proinflammatory cytokine expression in human cardiac myofibroblasts. Am J Physiol Heart Circ Physiol 2009; 297: H1117-H1127.
163. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360: 2426-2437.
164. Reddy S, Jia S, Geoffrey R, Lorier R, Suchi M, Broeckel U et al. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N Engl J Med 2009; 360: 2438-2444.
165. Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford, England) 2015; 54: 2134-2144.
166. Graudal NA, Svenson M, Tarp U, Garred P, Jurik A-G, Bendtzen K. Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis 2002; 61: 598-602.
167. Coleman KM, Gudjonsson JE, Stecher M. Open-label trial of MABp1, a true human monoclonal antibody targeting interleukin 1α, for the treatment of psoriasis. JAMA Dermatol 2015; 151: 555-556.
168. Sheedy FJ, Moore KJ. IL-1 signaling in atherosclerosis: sibling rivalry. Nat Immunol 2013; 14: 1030-1032.
169. Spears LD, Razani B, Semenkovich CF. Interleukins and atherosclerosis: a dysfunctional family grows. Cell Metab 2013; 18: 614-616.
170. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23: 656-660.
171. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H et al. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein E-deficient mice. Atherosclerosis 2011; 216: 313-320.
172. Kamari Y, Werman-Venkert R, Shaish A, Werman A, Harari A, Gonen A et al. Differential role and tissue specificity of interleukin- 1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis 2007; 195: 31-38.
173. Kamari Y, Shaish A, Shemesh S, Vax E, Grosskopf I, Dotan S et al. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin- 1α. Biochem Biophys Res Commun 2011; 405: 197-203.
174. Freigang S, Ampenberger F, Weiss A, Kanneganti T-D, Iwakura Y, Hersberger M et al. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis. Nat Immunol 2013; 14: 1045-1053.
175. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004; 4: 641-648.
176. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013; 13: 759-771.
177. DeNardo DG, Johansson M, Coussens LM. Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 2008; 27: 11-18.
178. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015; 125: 3347-3355.
179. Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M. IL-1RMyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 2012; 209: 1689-1702.
180. Qin Y, Ekmekcioglu S, Liu P, Duncan LM, Lizée G, Poindexter N et al. Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res 2011; 9: 1537-1550.
181. Tjomsland V, Spångeus A, Välilä J, Sandström P, Borch K, Druid H et al. Interleukin 1α sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia 2011; 13: 664-675.
182. Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M et al. The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis. J Immunol 2009; 183: 4705-4714.
183. Voronov E, Dotan S, Krelin Y, Song X, Elkabets M, Carmi Y et al. Unique versus redundant functions of IL-1α and IL-1β in the tumor microenvironment. Front Immunol 2013; 4: 177.
184. Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 2014; 15: 656-666.
185. Palmer G, Trolliet S, Talabot-Ayer D, Mézin F, Magne D, Gabay C. Pre-interleukin-1alpha expression reduces cell growth and increases interleukin-6 production in SaOS-2 osteosarcoma cells: Differential inhibitory effect of interleukin-1 receptor antagonist (icIL-1Ra1). Cytokine 2005; 31: 153-160.
186. Song X, Voronov E, Dvorkin T, Fima E, Cagnano E, Benharroch D et al. Differential effects of IL-1 alpha and IL-1 beta on tumorigenicity patterns and invasiveness. J Immunol 2003; 171: 6448-6456.
187. Dvorkin T, Song X, Argov S, White RM, Zoller M, Segal S et al. Immune phenomena involved in the in vivo regression of fibrosarcoma cells expressing cell-associated IL-1alpha. J Leukoc Biol 2006; 80: 96-106.
188. Voronov E, Weinstein Y, Benharroch D, Cagnano E, Ofir R, Dobkin M et al. Antitumor and immunotherapeutic effects of activated invasive T lymphoma cells that display short-term interleukin 1alpha expression. Cancer Res 1999; 59: 1029-1035.
189. Carriere V, Roussel L, Ortega N, Lacorre D-A, Americh L, Aguilar L et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 2007; 104: 282-287.
190. Baekkevold ES, Roussigné M, Yamanaka T, Johansen F-E, Jahnsen FL, Amalric F et al. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003; 163: 69-79.
191. Moussion C, Ortega N, Girard J-P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One 2008; 3: e3331.
192. Roussel L, Erard M, Cayrol C, Girard J-P. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9: 1006-1012.
193. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009; 183: 7890-7897.
194. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009; 284: 19420-19426.
195. Cayrol C, Girard J-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA 2009; 106: 9021-9026.
196. Lüthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31: 84-98.
197. Lefrançais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard J-P et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci USA 2012; 109: 1673-1678.
198. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490.
199. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179: 2551-2555.
200. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 2007; 104: 18660-18665.
201. Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E et al. Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation. Nat Comms 2015; 6: 8327.
202. Moulin D, Donzé O, Talabot-Ayer D, Mézin F, Palmer G, Gabay C. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007; 40: 216-225.
203. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179: 2051-2054.
204. Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.
205. Komai-Koma M, Xu D, Li Y, McKenzie ANJ, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007; 37: 2779-2786.
206. Iwahana H, Yanagisawa K, Ito-Kosaka A, Kuroiwa K, Tago K, Komatsu N et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999; 264: 397-406.
207. Hayakawa H, Hayakawa M, Kume A, Tominaga S-I. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007; 282: 26369-26380.
208. Xu D, Chan WL, Leung BP, Huang FP, Wheeler R, Piedrafita D et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187: 787-794.
209. Walzl G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw PJ et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med 2001; 193: 785-792.
210. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol 2008; 180: 2443-2449.
211. Alves-Filho JC, Sônego F, Souto FO, Freitas A, Verri WA, Auxiliadora- Martins M et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med 2010; 16: 708-712.
212. Préfontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183: 5094-5103.
213. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183: 6469-6477.
214. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009; 179: 772-781.
215. Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med 1999; 190: 895-902.
216. Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun 2009; 386: 181-185.
217. Kearley J, Silver JS, Sanden C, Liu Z, Berlin AA, White N et al. Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. Immunity 2015; 42: 566-579.
218. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
219. Mohan A, Chandra S, Agarwal D, Guleria R, Broor S, Gaur B et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010; 15: 536-542.
220. Mallia P, Message SD, Gielen V, Contoli M, Gray K, Kebadze T et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183: 734-742.
221. Miller AM, Xu D, Asquith DL, Denby L, Li Y, Sattar N et al. IL-33 reduces the development of atherosclerosis. J Exp Med 2008; 205: 339-346.
222. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2010; 107: 650-658.
223. Xu D, Jiang H-R, Kewin P, Li Y, Mu R, Fraser AR et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA 2008; 105: 10913-10918.
224. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum 2009; 60: 738-749.
225. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 2010; 37: 18-25.
226. Gross SR, Sin CGT, Barraclough R, Rudland PS. Joining S100 proteins and migration: for better or for worse, in sickness and in health. Cell Mol Life Sci 2014; 71: 1551-1579.
227. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ et al. Functions of S100 proteins. Curr Mol Med 2013; 13: 24-57.
228. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 2009; 1793: 993-1007.
229. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 2004; 322: 1111-1122.
230. Lu J, Esposito G, Scuderi C, Steardo L, Delli-Bovi LC, Hecht JL et al. S100B and APP promote a gliocentric shift and impaired neurogenesis in Down syndrome neural progenitors. PLoS One 2011; 6: e22126.
231. Esposito G, Imitola J, Lu J, De Filippis D, Scuderi C, Ganesh VS et al. Genomic and functional profiling of human Down syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Hum Mol Genet 2008; 17: 440-457.
232. Gogas H, Eggermont AMM, Hauschild A, Hersey P, Mohr P, Schadendorf D et al. Biomarkers in melanoma. Ann Oncol 2009; 20: vi8-v13.
233. Díaz-Lagares A, Alegre E, Arroyo A, González-Cao M, Zudaire ME, Viteri S et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol 2011; 32: 1155-1161.
234. Fritz G, Botelho HM, Morozova-Roche LA, Gomes CM. Natural and amyloid self-assembly of S100 proteins: structural basis of functional diversity. FEBS J 2010; 277: 4578-4590.
235. Leśniak W, Graczyk-Jarzynka A. The S100 proteins in epidermis: topology and function. Biochim Biophys Acta 2015; 1850: 2563-2572.
236. Duarte-Costa S, Castro-Ferreira R, Neves JS, Leite-Moreira AF. S100A1: a major player in cardiovascular performance. Physiol Res 2014; 63: 669-681.
237. Miwa N, Uebi T, Kawamura S. S100-annexin complexes-biology of conditional association. FEBS J 2008; 275: 4945-4955.
238. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer 2008; 123: 2370-2376.
239. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001; 69: 986-994.
240. Foell D, Seeliger S, Vogl T, Koch H-G, Maschek H, Harms E et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax 2003; 58: 613-617.
241. Gazzolo D, Michetti F. Perinatal S100B protein assessment in human unconventional biological fluids: a minireview and new perspectives. Cardiovasc Psychiatry Neurol 2010; 2010: 703563.
242. Dassan P, Keir G, Brown MM. Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis 2009; 27: 295-302.
243. Bloomfield SM, McKinney J, Smith L, Brisman J. Reliability of S100B in predicting severity of central nervous system injury. Neurocrit Care 2007; 6: 121-138.
244. Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calciumbinding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004; 344: 37-51.
245. Oesterle A, Hofmann Bowman MA. S100A12 and the S100/ calgranulins: emerging biomarkers for atherosclerosis and possibly therapeutic targets. Arterioscler Thromb Vasc Biol 2015; 35: 2496-2507.
246. Altwegg LA, Neidhart M, Hersberger M, Müller S, Eberli FR, Corti R et al. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 2007; 28: 941-948.
247. Vogl T, Ludwig S, Goebeler M, Strey A, Thorey IS, Reichelt R et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 2004; 104: 4260-4268.
248. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkötter C et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticularonset juvenile rheumatoid arthritis. Arthritis Rheum 2000; 43: 628-637.
249. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 9496-9502.
250. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W et al. Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in host defense against Candida albicans. PLoS Pathog 2009; 5: e1000639.
251. Riuzzi F, Sorci G, Donato R. S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGFdependent manner. J Cell Sci 2011; 124: 2389-2400.
252. Sorci G, Giovannini G, Riuzzi F, Bonifazi P, Zelante T, Zagarella S et al. The danger signal S100B integrates pathogen- and dangersensing pathways to restrain inflammation. PLoS Pathog 2011; 7: e1001315.
253. Schiavi P, Laccarino C, Servadei F. The value of the calcium binding protein S100 in the management of patients with traumatic brain injury. Acta Biomed 2012; 83: 5-20.
254. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemelä O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 2004; 56: 1229-1234; discussion 1234.
255. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97: 889-901.
256. Xie J, Burz DS, He W, Bronstein IB, Lednev I, Shekhtman A. Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches. J Biol Chem 2007; 282: 4218-4231.
257. Moroz OV, Burkitt W, Wittkowski H, He W, Ianoul A, Novitskaya V et al. Both Ca2+ and Zn2+ are essential for S100A12 protein oligomerization and function. BMC Biochem. 2009; 10: 11.
258. Srikrishna G, Nayak J, Weigle B, Temme A, Foell D, Hazelwood L et al. Carboxylated N-glycans on RAGE promote S100A12 binding and signaling. J Cell Biochem 2010; 110: 645-659.
259. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J et al. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
260. Ostendorp T, Leclerc E, Galichet A, Koch M, Demling N, Weigle B et al. Structural and functional insights into RAGE activation by multimeric S100B. EMBO J 2007; 26: 3868-3878.
261. Leclerc E, Fritz G, Weibel M, Heizmann CW, Galichet A. S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 2007; 282: 31317-31331.
262. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D. S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 2006; 312: 184-197.
263. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011; 9: 133-148.
264. Björk P, Björk A, Vogl T, Stenström M, Liberg D, Olsson A et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009; 7: e97.
265. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MAD et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049.
266. Fassl SK, Austermann J, Papantonopoulou O, Riemenschneider M, Xue J, Bertheloot D et al. Transcriptome assessment reveals a dominant role for TLR4 in the activation of human monocytes by the alarmin MRP8. J Immunol 2015; 194: 575-583.
267. Yan WX, Armishaw C, Goyette J, Yang Z, Cai H, Alewood P et al. Mast cell and monocyte recruitment by S100A12 and its hinge domain. J Biol Chem 2008; 283: 13035-13043.
268. Cornish CJ, Devery JM, Poronnik P, Lackmann M, Cook DI, Geczy CL. S100 protein CP-10 stimulates myeloid cell chemotaxis without activation. J Cell Physiol 1996; 166: 427-437.
269. Kerkhoff C, Sorg C, Tandon NN, Nacken W. Interaction of S100A8/ S100A9-arachidonic acid complexes with the scavenger receptor CD36 may facilitate fatty acid uptake by endothelial cells. Biochemistry 2001; 40: 241-248.
270. Hoppmann S, Steinbach J, Pietzsch J. Scavenger receptors are associated with cellular interactions of S100A12 in vitro and in vivo. Int J Biochem Cell Biol 2010; 42: 651-661.
271. Robinson MJ, Tessier P, Poulsom R, Hogg N. The S100 family heterodimer, MRP-8/14, binds with high affinity to heparin and heparan sulfate glycosaminoglycans on endothelial cells. J Biol Chem 2002; 277: 3658-3665.
272. Lim SY, Raftery MJ, Goyette J, Hsu K, Geczy CL. Oxidative modifications of S100 proteins: functional regulation by redox. J Leukoc Biol 2009; 86: 577-587.
273. Lim SY, Raftery MJ, Geczy CL. Oxidative modifications of DAMPs suppress inflammation: the case for S100A8 and S100A9. Antioxid Redox Signal 2011; 15: 2235-2248.
274. Ma W, Lee SE, Guo J, Qu W, Hudson BI, Schmidt AM et al. RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci. 2007; 48: 1355-1361.
275. Rohde D, Schön C, Boerries M, Didrihsone I, Ritterhoff J, Kubatzky KF et al. S100A1 is released from ischemic cardiomyocytes and signals myocardial damage via Toll-like receptor 4. EMBO Mol Med 2014; 6: 778-794.
276. Bi H, Yang Y, Huang J, Li Y, Ma C, Cong B. Immunohistochemical detection of S100A1 in the postmortem diagnosis of acute myocardial infarction. Diagn Pathol 2013; 8: 84.
277. Schneider M, Kostin S, Strøm CC, Aplin M, Lyngbaek S, Theilade J et al. S100A4 is upregulated in injured myocardium and promotes growth and survival of cardiac myocytes. Cardiovasc Res 2007; 75: 40-50.
278. Wu Y, Li Y, Zhang C, Wang X. A. Y, Cui W, Li H et al. S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-induced cardiac inflammation and injury. Hypertension 2014; 63: 1241-1250.
279. Tsoporis JN, Izhar S, Leong-Poi H, Desjardins JF, Huttunen HJ, Parker TG. S100B interaction with the receptor for advanced glycation end products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ. Res. 2010; 106: 93-101.
280. Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM. Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013; 25: 2185-2197.
281. Tsoporis JN, Izhar S, Proteau G, Slaughter G, Parker TG. S100B-RAGE dependent VEGF secretion by cardiac myocytes induces myofibroblast proliferation. Journal of Molecular and Cellular Cardiology 2012; 52: 464-473.
282. Goyette J, Yan WX, Yamen E, Chung YM, Lim SY, Hsu K et al. Pleiotropic roles of S100A12 in coronary atherosclerotic plaque formation and rupture. J Immunol 2009; 183: 593-603.
283. Hofmann Bowman MA, Gawdzik J, Bukhari U, Husain AN, Toth PT, Kim G et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc. Biol 2011; 31: 337-344.
284. Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA. Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol 2011; 33: 250-259.
285. Burton DGA, Matsubara H, Ikeda K. Pathophysiology of vascular calcification: Pivotal role of cellular senescence in vascular smooth muscle cells. Exp Gerontol 2010; 45: 819-824.
286. McCormick MM, Rahimi F, Bobryshev YV, Gaus K, Zreiqat H, Cai H et al. S100A8 and S100A9 in human arterial wall. Implications for atherogenesis. J Biol Chem 2005; 280: 41521-41529.
287. Farris SD, Hu JH, Krishnan R, Emery I, Chu T, Du L et al. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem 2011; 286: 22665-22677.
288. Nagareddy PR, Murphy AJ, Stirzaker RA, Hu Y, Yu S, Miller RG et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 2013; 17: 695-708.
289. Mortensen OH, Nielsen AR, Erikstrup C, Plomgaard P, Fischer CP, Krogh-Madsen R et al. Calprotectin-a novel marker of obesity. PLoS One 2009; 4: e7419.
290. Catalán V, Gómez-Ambrosi J, Rodríguez A, Ramírez B, Rotellar F, Valentí V et al. Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss. Mol Med 2011; 17: 1157-1167.
291. Perera C, McNeil HP, Geczy CL. S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol 2010; 88: 41-49.
292. Odink K, Cerletti N, Brüggen J, Clerc RG, Tarcsay L, Zwadlo G et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987; 330: 80-82.
293. Baillet A, Trocmé C, Berthier S, Arlotto M, Grange L, Chenau J et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford, England) 2010; 49: 671-682.
294. Wittkowski H, Foell D, af Klint E, De Rycke L, De Keyser F, Frosch M et al. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1020-1025.
295. Sunahori K, Yamamura M, Yamana J, Takasugi K, Kawashima M, Yamamoto H et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R69.
296. van Lent PLEM, Grevers LC, Blom AB, Arntz OJ, van de Loo FAJ, van der Kraan P et al. Stimulation of chondrocyte-mediated cartilage destruction by S100A8 in experimental murine arthritis. Arthritis Rheum 2008; 58: 3776-3787.
297. Schelbergen RFP, Blom AB, van den Bosch MHJ, Sloetjes A, Abdollahi-Roodsaz S, Schreurs BW et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on toll-like receptor 4. Arthritis Rheum 2011; 64: 1477-1487.
298. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135.
299. Kane D, Roth J, Frosch M, Vogl T, Bresnihan B, FitzGerald O. Increased perivascular synovial membrane expression of myeloidrelated proteins in psoriatic arthritis. Arthritis Rheum 2003; 48: 1676-1685.
300. Loeser RF, Yammani RR, Carlson CS, Chen H, Cole A, Im H-J et al. Articular chondrocytes express the receptor for advanced glycation end products: potential role in osteoarthritis. Arthritis Rheum 2005; 52: 2376-2385.
301. Yammani RR, Carlson CS, Bresnick AR, Loeser RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. Arthritis Rheum 2006; 54: 2901-2911.
302. Madsen P, Rasmussen HH, Leffers H, Honoré B, Celis JE. Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol 1992; 99: 299-305.
303. Broome A-M, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 2003; 51: 675-685.
304. Nukui T, Ehama R, Sakaguchi M, Sonegawa H, Katagiri C, Hibino T et al. S100A8/A9, a key mediator for positive feedback growth stimulation of normal human keratinocytes. J Cell Biochem 2008; 104: 453-464.
305. Wolf R, Howard OMZ, Dong H-F, Voscopoulos C, Boeshans K, Winston J et al. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 2008; 181: 1499-1506.
306. Zheng Y, Niyonsaba F, Ushio H, Ikeda S, Nagaoka I, Okumura K et al. Microbicidal protein psoriasin is a multifunctional modulator of neutrophil activation. Immunology 2008; 124: 357-367.
307. Jinquan T, Vorum H, Larsen CG, Madsen P, Rasmussen HH, Gesser B et al. Psoriasin: a novel chemotactic protein. J Invest Dermatol 1996; 107: 5-10.
308. Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer 2015; 15: 96-109.
309. Nasser MW, Elbaz M, Ahirwar DK, Ganju RK. Conditioning solid tumor microenvironment through inflammatory chemokines and S100 family proteins. Cancer Lett 2015; 365: 11-22.
310. Leclerc E, Vetter SW. The role of S100 proteins and their receptor RAGE in pancreatic cancer. Biochim Biophys Acta 2015; 1852: 2706-2711.